CTI BioPharma

About:

CTI BioPharma is a biopharmaceutical company developing oncology products for the treatment of blood-related cancers.

Website: http://www.ctibiopharma.com

Twitter/X: CTIBioPharma

Top Investors: Hercules Capital, DRI Healthcare Trust, New Enterprise Associates

Description:

CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in a first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.